<unk>  is an kinase inhibitor that is FDA approved for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.   Common adverse reactions include decreased left ventricular ejection fraction (LVEF), pneumonitis, renal failure, diarrhea, and rash.
Trametinib
Binimetinib
Cobimetinib
Stibine
Nilotinib
Gefitinib
Erlotinib
Taxane